Navigation Links
MitraClip(R) Therapy Data Demonstrate Clinical Benefit in High-Risk Patients With Mitral Regurgitation
Date:5/20/2009

EVEREST High-Risk Registry Data Show Improved Symptomatic Status, Cardiac Function and Reduced rate of Hospitalization for Congestive Heart Failure in both Functional and Degenerative MR Patient Populations

BARCELONA, Spain, May 20 /PRNewswire/ -- Results show percutaneous mitral repair using the MitraClip(R) system in symptomatic high-risk surgical patients with either functional mitral regurgitation (FMR) or degenerative mitral regurgitation (DMR) improves patient clinical status. The results from the 78 patient EVEREST II High Risk Registry demonstrated improvement in left ventricular function and reduced hospitalization for congestive heart failure for both MR groups at twelve months. Additionally, a reduction in mortality compared to the predicted mortality risk of surgery was reported for the registry. The results of the High-Risk Registry were presented today at the third annual meeting of EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

MR is the most common type of heart valve insufficiency in Europe and the United States, affecting millions of people worldwide. Significant MR affects more than eight million people in the US and Europe, the majority of which have FMR. There are more than 600,000 new diagnoses of significant MR each year in Europe and the US; however only 20 percent of these patients undergo surgery each year. Many higher risk surgical patients and non-surgical patients continue to be affected by the chronic volume overload caused by MR, which requires the heart to work harder, and may ultimately lead to heart failure.

The data were presented today by Saibal Kar, M.D., director of interventional cardiac research at Cedars-Sinai Medical Center and the lead enrolling investigator of the EVEREST trials.

"The High Risk Registry data support our belief that the MitraClip therapy is a safe and clinically bene
'/>"/>

SOURCE Evalve, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
2. First Swiss Patients Treated with the Percutaneous MitraClip(R) System
3. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
4. First European Patients Treated With the Percutaneous MitraClip(R) System
5. New Data Shows Ongoing Benefits of Percutaneous MitraClip(R) Device for Patients With Mitral Regurgitation
6. New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy
7. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
8. CVS Caremark Data Confirms Improved Outcomes for Women with Osteoporosis Who are Adherent to Therapy
9. New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure
10. Prostate Cancer Immunotherapy Significantly Prolongs Survival in Men With Advanced Prostate Cancer
11. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014   Decision Resources Group finds that ... chronic kidney disease non-dialysis (CKD-ND) patients are not ... In addition, one-year persistency is similar between Amgen,s ... key findings from the report entitled ... Stimulating Agents in Late Stage Chronic Kidney Disease ...
(Date:9/30/2014)... Ind. , Sept. 30, 2014  The orthopedic specialists ... the nation,s No. 6 orthopedic group by US News ... Active Adults," a series of free, public seminars to ... all over the world come to see the knee ... procedures are now available at Munster Specialty Surgery Center. ...
(Date:9/30/2014)... In 2011, approximately 5.1 million people in ... pain relievers (e.g. opioids). 1 Clinical treatments for ... the use of buprenorphine, buprenorphine/naloxone, naltrexone or methadone. The ... developing and improving care management programs, according to ... Therapeutics LLC (Prime). Cost trends ...
Breaking Medicine Technology:Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3
... UCB) and U.S. based partner Immunomedics Inc. (Nasdaq: ... IIb study, EMBLEM™, showed that certain doses of epratuzumab ... in disease activity in adult patients with moderate to ... designed to evaluate the efficacy and safety of epratuzumab ...
... innovator of Packaging Execution Systems (PES) for the pharmaceutical ... engineering, automation and manufacturing optimization services company, today announced ... Service Provider (SSP). VCG will now sell, install and ... United States. The SSP program is ...
Cached Medicine Technology:Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 2Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 3Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 4Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 5Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 6Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 7Systech International and Vantage Consulting Group Partner to Address Emerging U.S. Pharmaceutical Regulatory Requirements 2Systech International and Vantage Consulting Group Partner to Address Emerging U.S. Pharmaceutical Regulatory Requirements 3
(Date:9/30/2014)... Health Day Reporter TUESDAY, ... who are overweight or obese when diagnosed appear to ... weight-related cancer, new research suggests. , , The finding ... only the potential for developing other cancers associated with ... who reported being overweight or obese prior to diagnosis ...
(Date:9/30/2014)... Symposia will convene the first conference of its 2014-2015 ... Series on "The Modes of Action of Vaccine ... the conclusion of the Grand Challenges Meeting for that ... Keystone Symposia Global Health Series, supported by the Bill ... awards for 36 investigators from developing countries to attend. ...
(Date:9/30/2014)... Integrated Medicine Alliance , Monmouth County’s ... medical specialty practice through a unique partnership with an ... located within the company’s Shrewsbury location and will be ... of American Heart Center, P.C., a highly regarded practice ... Integrated Medicine Alliance patients top notch cardiovascular care without ...
(Date:9/30/2014)... team has been awarded a three-year $1.7 million ... to develop new imaging technologies and data analysis ... large networks of neurons in the brain interact ... researchers identify the precise interactions between millions of ... speaking, and alterations in these interactions that may ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... is helping people perform better in and out of the ... and memory has caught the attention of Shane Michaels, prompting ... day-to-day grind, fatigue is the reason most people simply just ... whether that means staying focused at work, getting the motivation ...
Breaking Medicine News(10 mins):Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2
... released software program will let health authorities at the ... speeding the detection of new cases and the implementation ... was developed by a team of epidemiologists and computer ... (MIDAS), an international program supported by the National Institutes ...
... Cover Election, Customer Service and Other Work Life Topics ... That Counter Recent ... those,surveyed in the 2007 Annual Work+Life Fit Reality Check believe the ... offer and individuals to have more work life flexibility.,The telephone survey ...
... Avani to Represent Dermatology Products Featuring Invisicare(R), ... Inc. (OTC,Bulletin Board: SKVI) / (Website: ... has signed a marketing agreement with Avani,International ... it was granted a comprehensive patent in ...
... Dec. 6 Insmed Inc. (Nasdaq:,INSM), a developer of ... at the IBC 5th Annual Global Follow-On Biologics,Conference on ... The conference, to be held at the Hyatt Regency ... through Tuesday, December,11th, and will bring together corporate, regulatory, ...
... Health, Inc. (Amex: OPK ),today reported that the ... of wet age-related macular degeneration (wet,AMD), was named one ... III,clinical trials during the third quarter of 2007. The ... to Watch report issued by Thomson,Scientific Inc. Thomson,s industry ...
... you get for the nut,that has everything, including more than ... talking therapy doll?, You can at once give a ... it, their own personal and portable psychotherapist. The,Ask Doctor Chuck ... could,earn you the undying gratitude of the rest of your ...
Cached Medicine News:Health News:New software to aid early detection of infectious disease outbreaks 2Health News:Employees Want the Next President's Agenda to Make Work Life Flexibility Easier for Companies and Individuals 2Health News:Employees Want the Next President's Agenda to Make Work Life Flexibility Easier for Companies and Individuals 3Health News:Employees Want the Next President's Agenda to Make Work Life Flexibility Easier for Companies and Individuals 4Health News:Employees Want the Next President's Agenda to Make Work Life Flexibility Easier for Companies and Individuals 5Health News:Skinvisible Signs Marketing Agreement for India 2Health News:Skinvisible Signs Marketing Agreement for India 3Health News:Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference 2Health News:OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials 2Health News:OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials 3Health News:OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials 4Health News:The Cure for Holiday Stress 2
The fat loss formula's key ingredient of 2.0% aminophylline works by penetrating deep into the skin where it causes the body fat cells to shrink, resulting in up to 2 inches of body fat loss....
... VelaSmooth is the first ... device with the revolutionary elos ... Radio Frequency and Infrared Light ... with suction to reduce the ...
... was designed with the physician, staff ... you the best economy exam room ... does not skimp on patient comfort. ... can easily position patients so that ...
The Salt A-Peel™ microdermabrasion combines, positive air pressure, pure salt, ultrasound and the application of rich anti oxidant products to deliver a remarkable 'The Salt A-Peel' anti ageing...
Medicine Products: